Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015 (2015), Article ID 834085, 15 pages
http://dx.doi.org/10.1155/2015/834085
Research Article

DC-Based Immunotherapy Combined with Low-Dose Methotrexate Effective in the Treatment of Advanced CIA in Mice

1JW CreaGene Research Institute, JW CreaGene Inc., Seongnam-si, Gyeonggi-do 462-120, Republic of Korea
2Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul 133-791, Republic of Korea
3Department of Biological Science, Sungkyunkwan University, Suwon, Gyeonggi-do 440-746, Republic of Korea

Received 28 January 2015; Revised 15 April 2015; Accepted 27 April 2015

Academic Editor: Patrizia Rovere-Querini

Copyright © 2015 Jun-Eui Park et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Chen, “Immunotherapy of rheumatoid arthritis targeting inflammatory cytokines and autoreactive T cells,” Archivum Immunologiae et Therapiae Experimentalis, vol. 58, no. 1, pp. 27–36, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Banchereau and R. M. Steinman, “Dendritic cells and the control of immunity,” Nature, vol. 392, no. 6673, pp. 245–252, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Banchereau, F. Briere, C. Caux et al., “Immunobiology of dendritic cells,” Annual Review of Immunology, vol. 18, pp. 767–811, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. R. M. Steinman and J. Banchereau, “Taking dendritic cells into medicine,” Nature, vol. 449, no. 7161, pp. 419–426, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. R. M. Steinman, D. Hawiger, and M. C. Nussenzweig, “Tolerogenic dendritic cells,” Annual Review of Immunology, vol. 21, pp. 685–711, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. H. S. Adler and K. Steinbrink, “Tolerogenic dendritic cells in health and disease: friend and foe!,” European Journal of Dermatology, vol. 17, no. 6, pp. 476–491, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. C. M. U. Hilkens, J. D. Isaacs, and A. W. Thomson, “Development of dendritic cell-based immunotherapy for autoimmunity,” International Reviews of Immunology, vol. 29, no. 2, pp. 156–183, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. B. J. O'Sullivan, S. Pai, S. Street et al., “Immunotherapy with costimulatory dendritic cells to control autoimmune inflammation,” The Journal of Immunology, vol. 187, no. 8, pp. 4018–4030, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Khan, J. D. Greenberg, and N. Bhardwaj, “Dendritic cells as targets for therapy in rheumatoid arthritis,” Nature Reviews Rheumatology, vol. 5, no. 10, pp. 566–571, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. J. N. Stoop, J. H. Robinson, and C. M. U. Hilkens, “Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models?” Annals of the Rheumatic Diseases, vol. 70, no. 9, pp. 1526–1533, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Giannoukakis, B. Phillips, D. Finegold, J. Harnaha, and M. Trucco, “Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients,” Diabetes Care, vol. 34, no. 9, pp. 2026–2032, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. C. M. U. Hilkens and J. D. Isaacs, “Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?” Clinical & Experimental Immunology, vol. 172, no. 2, pp. 148–157, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Thomas, S. Street, and N. Ranmoruth, “Safety and preliminary evidence of efficacy in a phase I clinical trial of autologous tolerising dendritic cells exposed to citullinated peptides (Rheumavax) in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 70, supplement 3, article 169, 2011. View at Google Scholar
  14. D.-S. Lim, M.-S. Kang, J.-A. Jeong, and Y.-S. Bae, “Semi-mature DC are immunogenic and not tolerogenic when inoculated at a high dose in collagen-induced arthritis mice,” European Journal of Immunology, vol. 39, no. 5, pp. 1334–1343, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Swierkot and J. Szechinski, “Methotrexate in rheumatoid arthritis,” Pharmacological Reports, vol. 58, no. 4, pp. 473–492, 2006. View at Google Scholar
  16. S. Xinqiang, L. Fei, L. Nan et al., “Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing partially CD4+CD25+Treg cells and inducing Th1 to Th2 shift in both cells and cytokines,” Biomedicine and Pharmacotherapy, vol. 64, no. 7, pp. 463–471, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. D. E. Furst, “The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases,” British Journal of Rheumatology, vol. 36, no. 11, pp. 1196–1204, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Lange, E. Bajtner, C. Rintisch, K. S. Nandakumar, U. Sack, and R. Holmdahl, “Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis,” Annals of the Rheumatic Diseases, vol. 64, no. 4, pp. 599–605, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. M. F. Neurath, K. Hildner, C. Becker et al., “Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression,” Clinical and Experimental Immunology, vol. 115, no. 1, pp. 42–55, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Herman, N. Zurgil, P. Langevitz, M. Ehrenfeld, and M. Deutsch, “Methotrexate selectively modulates TH1/TH2 balance in active rheumatoid arthritis patients,” Clinical & Experimental Rheumatology, vol. 26, no. 2, pp. 317–323, 2008. View at Google Scholar · View at Scopus
  21. M. A. Miah, C.-H. Yoon, J. Kim, J. Jang, Y.-R. Seong, and Y.-S. Bae, “CISH is induced during DC development and regulates DC-mediated CTL activation,” European Journal of Immunology, vol. 42, no. 1, pp. 58–68, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. M. A. Miah, S. E. Byeon, M. S. Ahmed, C.-H. Yoon, S.-J. Ha, and Y.-S. Bae, “Egr2 induced during DC development acts as an intrinsic negative regulator of DC immunogenicity,” European Journal of Immunology, vol. 43, no. 9, pp. 2484–2496, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. J.-K. Yi, H.-J. Kim, D.-H. Yu et al., “Regulation of inflammatory responses and fibroblast-like synoviocyte apoptosis by calcineurin-binding protein 1 in mice with collagen-induced arthritis,” Arthritis and Rheumatism, vol. 64, no. 7, pp. 2191–2200, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. J. B. Imboden, “The immunopathogenesis of rheumatoid arthritis,” Annual Review of Pathology: Mechanisms of Disease, vol. 4, pp. 417–434, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. I. Popov, M. Li, X. Zheng et al., “Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine,” Arthritis Research & Therapy, vol. 8, no. 5, article R141, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Takagishi, T. Hotokebuchi, K. Arai, C. Arita, and N. Kaibara, “Collagen arthritis in rats: the importance of humoral immunity in the initiation of the disease and perpetuation of the disease by suppressor T cells,” International Reviews of Immunology, vol. 4, no. 1, pp. 35–48, 1988. View at Publisher · View at Google Scholar · View at Scopus
  27. M. B. Litinskiy, B. Nardelli, D. M. Hilbert et al., “DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL,” Nature Immunology, vol. 3, no. 9, pp. 822–829, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Salazar, O. Aravena, P. Abello et al., “Modulation of established murine collagen-induced arthritis by a single inoculation of short-term lipopolysaccharide-stimulated dendritic cells,” Annals of the Rheumatic Diseases, vol. 67, no. 9, pp. 1235–1241, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. W. Chen, X. Liang, A. J. Peterson, D. H. Munn, and B. R. Blazar, “The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation,” The Journal of Immunology, vol. 181, no. 8, pp. 5396–5404, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. O. Manches, D. Munn, A. Fallahi et al., “HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism,” The Journal of Clinical Investigation, vol. 118, no. 10, pp. 3431–3439, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. D. J. Chung, M. Rossi, E. Romano et al., “Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells,” Blood, vol. 114, no. 3, pp. 555–563, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. M. A. Lopez-Olivo, J. H. Tayar, J. A. Martinez-Lopez et al., “Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis,” The Journal of the American Medical Association, vol. 308, no. 9, pp. 898–908, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. I. Navarro-Millán and J. R. Curtis, “Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis,” Current Opinion in Rheumatology, vol. 25, no. 3, pp. 384–390, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. P. A. van Schouwenburg, C. L. Krieckaert, M. Nurmohamed et al., “IgG4 production against adalimumab during long term treatment of RA patients,” Journal of Clinical Immunology, vol. 32, no. 5, pp. 1000–1006, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. P. A. van Schouwenburg, L. A. van de Stadt, R. N. de Jong et al., “Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation,” Annals of the Rheumatic Diseases, vol. 72, no. 1, pp. 104–109, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. C. C. Mok, D. van der Kleij, and G. J. Wolbink, “Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases,” Clinical Rheumatology, vol. 32, no. 10, pp. 1429–1435, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Idoyaga, C. Fiorese, L. Zbytnuik et al., “Specialized role of migratory dendritic cells in peripheral tolerance induction,” The Journal of Clinical Investigation, vol. 123, no. 2, pp. 844–854, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Liu, T. Iyoda, M. Saternus, Y. Kimura, K. Inaba, and R. M. Steinman, “Immune tolerance after delivery of dying cells to dendritic cells in situ,” The Journal of Experimental Medicine, vol. 196, no. 8, pp. 1091–1097, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. R. M. Steinman, S. Turley, I. Mellman, and K. Inaba, “The induction of tolerance by dendritic cells that have captured apoptotic cells,” The Journal of Experimental Medicine, vol. 191, no. 3, pp. 411–416, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Zhao, A. Zhang, H. Du, S. Guo, B. Ning, and S. Yang, “Tolerogenic dendritic cells and rheumatoid arthritis: current status and perspectives,” Rheumatology International, vol. 32, no. 4, pp. 837–844, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Martin, C. Capini, E. Duggan et al., “Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-κB,” Arthritis & Rheumatism, vol. 56, no. 7, pp. 2255–2266, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Lu, A. Gambotto, W.-C. Lee et al., “Adenoviral delivery of CTLA4lg into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic recipients,” Gene Therapy, vol. 6, no. 4, pp. 554–563, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. S. H. Kim, C. H. Evans, S. C. Ghivizzani, T. Oligino, and P. D. Robbins, “Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4,” The Journal of Immunology, vol. 166, no. 5, pp. 3499–3505, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. Morita, J. Yang, R. Gupta et al., “Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis,” The Journal of Clinical Investigation, vol. 107, no. 10, pp. 1275–1284, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. P. T. H. Coates, R. Krishnan, S. Kireta, J. Johnston, and G. R. Russ, “Human myeloid dendritic cells transduced with an adenoviral interleukin-10 gene construct inhibit human skin graft rejection in humanized NOD-scid chimeric mice,” Gene Therapy, vol. 8, no. 16, pp. 1224–1233, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. P. H. Tan, J. B. Yates, S.-A. Xue et al., “Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression,” Blood, vol. 106, no. 9, pp. 2936–2943, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. S. H. Kim, S. Kim, T. J. Oligino, and P. D. Robbins, “Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express fasl,” Molecular Therapy, vol. 6, no. 5, pp. 584–590, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. Z. Liu, X. Xu, H.-C. Hsu et al., “CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis,” The Journal of Clinical Investigation, vol. 112, no. 9, pp. 1332–1341, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. X. Liang, L. Lu, Z. Chen et al., “Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival,” Transplantation, vol. 76, no. 4, pp. 721–729, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Li, X. Zheng, I. Popov et al., “Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis,” Journal of Translational Medicine, vol. 10, no. 1, article 19, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. K. Steinbrink, M. Wölfl, H. Jonuleit, J. Knop, and A. H. Enk, “Induction of tolerance by IL-10-treated dendritic cells,” The Journal of Immunology, vol. 159, no. 10, pp. 4772–4780, 1997. View at Google Scholar · View at Scopus
  52. D. Yarilin, R. Duan, Y.-M. Huang, and B.-G. Xiao, “Dendritic cells exposed in vitro to TGF-β1 ameliorate experimental autoimmune myasthenia gravis,” Clinical and Experimental Immunology, vol. 127, no. 2, pp. 214–219, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. M. A. Boks, J. R. Kager-Groenland, M. S. P. Haasjes, J. J. Zwaginga, S. M. van Ham, and A. ten Brinke, “IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction—a comparative study of human clinical-applicable DC,” Clinical Immunology, vol. 142, no. 3, pp. 332–342, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. H. R. Turnquist, G. Raimondi, A. F. Zahorchak, R. T. Fischer, Z. Wang, and A. W. Thomson, “Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance,” The Journal of Immunology, vol. 178, no. 11, pp. 7018–7031, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. L. M. van Duivenvoorde, P. Louis-Plence, F. Apparailly et al., “Antigen-specific immunomodulation of collagen-induced arthritis with tumor necrosis factor-stimulated dendritic cells,” Arthritis and Rheumatism, vol. 50, no. 10, pp. 3354–3364, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. C. Voigtländer, S. Rößner, E. Cierpka et al., “Dendritic cells matured with TNF can be further activated in vitro and after subcutaneous injection in vivo which converts their tolerogenicity into immunogenicity,” Journal of Immunotherapy, vol. 29, no. 4, pp. 407–415, 2006. View at Publisher · View at Google Scholar · View at Scopus